Galanin, a brain-gut peptide, is also synthesized and released by the pituitary. In man, galanin-like immunoreactivity and galanin messenger RNA have been detected specifically in normal and tumoral corticotropes, but little is known about the production and release of galanin by the human pituitary. We evaluated galanin release by 5 ACTHsecreting pituitary adenomas in culture and plasma galanin concentrations in the inferior petrosal sinuses (IPSs) of 15 patients with Cushing's disease before and after CRH administration. For comparison, the galanin response to CRH was evaluated in 8 normal controls.
Basal and CRH-stimulated ACTH and galanin concentrations also exhibited a strong positive correlation in single tumor cultures.
At IPS sampling, mean basal plasma galanin concentrations in the dominant IPS were somewhat higher than those registered at the periphery (18.6 Ϯ 1.94 vs. 15.8 Ϯ 1.60 pmol/L, P ϭ 0.05). Administration of CRH induced a modest but significant increase in galanin concentrations at all three sampling sites. No correlations were found between ACTH and galanin levels in the IPSs and at the periphery. Different from what was observed in patients with Cushing's disease, CRH did not modify plasma galanin concentrations in normal subjects.
In conclusion, this study demonstrates that galanin is released by human tumoral corticotropes and responds to CRH. The role of locally produced galanin is, as yet, unknown but may possibly be that of a autocrine/paracrine modulator. (J Clin Endocrinol Metab 84: [1351] [1352] [1353] [1354] [1355] [1356] 1999) T HE PAST several years brought to light the regulatory role that galanin, a brain-gut peptide, exerts within the hypothalamic-pituitary system. Galanin is, in fact, synthesized and secreted in several hypothalamic nuclei, colocalized with neuropeptides and neurotransmitters, and released into the hypophysial portal blood (for review, see Refs. 1 and 2). Further, galanin-binding sites (3, 4) and galanin receptor messenger RNA (5, 6) have been detected in both the hypothalamus and the pituitary. Galanin is also synthesized and released by the pituitary itself, and studies carried out in rodents demonstrated that pituitary galanin content and release is modulated by several hormones, peptides, and neurotransmitters, thus identifying galanin as a pituitary hormone (1) . In addition, galanin seems to act as a paracrine/autocrine factor within the anterior pituitary (7) (8) (9) (10) .
In the rat, galanin plays an important role in stimulating the preovulatory LH surge (11) and is a potent stimulus for GH and PRL secretion (1, 2, 4, 12) . By comparison, in man, the best known action of galanin is the stimulation of GH secretion (1) whereas potentiation of PRL release seems to be more subtle (13) (14) (15) (16) , and no effect on gonadotrope secretions has been observed (13, 16, 17) . As regards the production of galanin by the human pituitary, galanin-like immunoreactivity and galanin messenger RNA have been detected only in normal corticotropes and in ACTH-secreting tumors (18, 19) , thus linking galanin to ACTH in man. On the basis of this evidence, we had previously evaluated the response of pituitary hormones to administration of exogenous galanin in patients with Cushing's disease (CD). In these patients, galanin induced a striking increase in PRL levels, by far greater than the one observed in normal subjects. We had therefore hypothesized that galanin produced by tumoral corticotropes might enhance the PRL response to exogenous galanin (14) .
The aim of this study was to establish whether galanin is released by human ACTH-secreting pituitary tumors and responds to CRH. To this purpose, we performed an in vitro and an in vivo protocol: 1) evaluation of galanin release by pituitary ACTH-producing tumors in culture; and 2) measurement of plasma galanin concentrations in the inferior petrosal sinuses (IPSs) and at the periphery before and after administration of CRH. For comparison, we also evaluated peripheral galanin levels after CRH administration in a group of normal subjects.
Materials and Methods

Pituitary cell cultures
Five pituitary, pathologically confirmed, ACTH-secreting adenomas were collected during transsphenoidal surgery, dispersed with 0.1% collagenase in HAM-F10, plated at a density of 2-3 ϫ 10 5 cells/well, and incubated at 37 C in DMEM, 10% FCS, 0.05 mg/mL ascorbic acid (Sigma Chemical Co., St. Louis, MO), 100 U/mL penicillin, 100 U/mL streptomycin, 10 mg/mL gentamycin, and 0.25 g/mL Amphotericin B in 5% CO 2 -95% O 2 for 4 days. Except for ascorbic acid, all reagents for cell culture had been purchased from Hyclone Laboratories Inc. Ltd, Cramlington, UK. On the day of the experiment, wells were washed in serumfree medium containing 0.1% BSA (Sigma Chemical Co.) for 1 h, before incubation with 100 pM-100 nM ovine CRH. Medium samples were collected at 4 and 24 h for ACTH and galanin measurement. Control wells were incubated with serum-free medium containing 0.1% BSA.
Each treatment was performed in triplicate or quadruplicate, according to cell availability.
Patients and in vivo protocol
Fifteen patients with surgically proven CD (4 men, 11 women, 20 -50 yr old) were submitted to IPS sampling. Before and 2, 5, 10, and 15 min after iv administration of 100 g CRH (ovine CRH, UCB Bioproducts, Brussels, Belgium), blood samples were collected simultaneously from a forearm vein and from each IPS, into prechilled polypropylene tubes containing EDTA (2 mg/mL) and aprotinine (500 kIU/mL). Samples were kept in ice and centrifuged within 1 h. Plasma was stored at Ϫ80 C for ACTH and galanin measurements. All patients presented a centerto-periphery ACTH gradient Ն 3 after CRH, whereas in 5 of 15 the interpetrosal gradient (Ն1.4) agreed with the site of the adenoma, as detected by surgery. In 8 healthy volunteers (2 men, 6 women, 18 -50 yr old), a CRH test and a placebo saline infusion were performed with sampling up to 120 min after the beginning of the test. Tests were performed in random order, at least 3 days apart, between 0830 and 0900 h, in fasted subjects. In 25 additional normal subjects (6 men, 19 women, 18 -49 yr old), a plasma sample for galanin measurement was collected in the morning, after an overnight fast. The study was approved by the Ethical Committee of our Institution, and informed consent was obtained from all participating subjects.
Peptide assays
Galanin in plasma samples was measured by RIA, as previously described (20) . Briefly, 2 mL plasma were acidified with an equal vol of 0.1% trifluoracetic acid (TFA) and centrifuged at 3000 ϫ g. Supernatants were applied onto reverse-phase minicolumns (Sep Column, Peninsula Laboratories Inc., Belmont, CA), washed with 0.1% TFA, and eluted with 3 mL 0.1% TFA/acetonitrile (4/6, vol/vol). Using this protocol, recovery of synthetic human galanin was 66%. RIA was performed using a rabbitantihuman galanin antiserum and human synthetic galanin as standard and tracer (Peninsula Laboratories, Inc.). The sensitivity of the assay is 12 pg/tube (5.7 pmol/L), and intra-and interassay coefficients of variation are 9.8% and 11.2%, respectively. Samples of patients with CD and controls were run together in each assay. Galanin in medium was assayed without prior extraction.
Plasma ACTH was measured by immunoradiometric assay (Allegro, Nichols Institute Diagnostics, San Juan Capistrano, CA). Sensitivity, intra-and interassay coefficients of variation are 0.22 pmol/L, 4.8%, and 8.9%, respectively. Medium ACTH concentrations were assayed by RIA, according to the manufacturer's instructions (IgG Corporation, Nashville, TN) using tracer obtained from Amersham International (Little Chalfont, UK). Sensitivity, intra-and interassay coefficients of variation are 0.1 pmol/L, 6.4%, and 6.9%, respectively.
Statistical analysis
The results of the in vivo study were compared using Student's t test for paired and unpaired data, as appropriate. Linear regression analysis was used to assess relationships between variables. A nonparametric ANOVA (Kruskal-Wallis test) was used to evaluate the statistical significance of percent increase over baseline. Data are expressed as mean Ϯ sem.
Results
ACTH and galanin release by human pituitary ACTH-secreting tumors in vitro
Unstimulated ACTH secretion differed widely among pituitary tumors in culture but increased markedly after CRH, at both 4 h and 24 h, in all patients (Fig. 1, left panels) . Basal galanin secretion at 4 h ranged from 30 -230 pmol/well and was strongly correlated with ACTH concentrations at the same timepoint (r ϭ 0.85, P Ͻ 0.001). Incubation with CRH induced an increase in galanin concentrations, which was evident already at 4 h in some patients and more readily apparent in all patients at 24 h (Fig. 1, middle panels) . The stimulatory effect of CRH on galanin release was dose-dependent; indeed, log-transformed CRH concentrations and galanin levels were strongly correlated (Fig. 1, right panels) . Overall mean galanin secretion at 24 h (expressed as percent of unstimulated levels) was 151 Ϯ 32% for 100 pM CRH, 232 Ϯ 43% for 1 nM CRH, 246 Ϯ 35% for 10 nM CRH, and
Mean galanin levels in all adenoma cultures after 4 h and 24 h of incubation with CRH. Bars, Percent increase over unstimulated levels with control wells set at 100%. Statistical significance was assessed using Kruskal-Wallis test. Ⅺ, Control wells; u, 100 pM CRH; p, 1 nM CRH; f, 10 nM CRH; z, 100 nM CRH. FIG. 3 . Correlation between ACTH and galanin concentrations after 24 h incubation in one representative adenoma culture. E, unstimulated; F, 100 pM CRH; Ⅺ, 1 nM CRH; ᭜, 10 nM CRH; , 100 nM CRH.
FIG. 1. ACTH (left panels) and galanin (middle panels) levels in individual adenoma cultures after 4 h and 24 h of incubation with CRH.
Correlation between log-transformed CRH concentrations and galanin levels in individual adenoma cultures at 24 h (right panels). Bars, Mean of 3-4 wells; Ⅺ, control wells; u, 100 pM CRH; p, 1 nM CRH; f, 10 nM CRH; z, 100 nM CRH.
270 Ϯ 44% for 100 nM CRH (P Ͻ 0.05, by Kruskal-Wallis; Fig.  2 ). In each tumor culture, ACTH and galanin concentrations at 24 h exhibited a strong positive correlation, and a representative example is shown in Fig. 3 .
Galanin plasma levels in patients with CD
Baseline peripheral plasma levels of galanin were comparable in patients with CD and 33 normal subjects (15.8 Ϯ 1.60 vs. 14.8 Ϯ 1.6 pmol/L, not significant). At IPS sampling, mean basal plasma galanin concentrations of the dominant IPS were slightly higher than those registered in peripheral blood (18.6 Ϯ 1.94 vs. 15.8 Ϯ 1.60 pmol/L, P ϭ 0.05). ACTH responded to CRH in all patients with CD (Fig. 4, upper panel) , whereas plasma galanin concentrations exhibited a variable increase (Fig. 4, lower panel) . A clear increment in galanin levels (defined as 30% over baseline, i.e. three times the intraassay coefficient of variation) was registered in 9 patients in the IPS and in 5 patients at the periphery. As a whole, In the eight normal subjects subjected to CRH testing, plasma ACTH levels rose significantly, whereas galanin concentrations were not different from those observed during saline infusion (data not shown). No correlations were found between plasma ACTH and galanin levels.
Discussion
Studies published so far on the secretion of galanin by the anterior pituitary have been carried out only in the rat. In this species, galanin is produced by lactotropes, somatotropes, and thyrotropes (21) and is modulated by estrogens (22, 23) , PRL (23), thyroid hormones (24), corticosteroids (21, 25) , and hypothalamic factors such as GHRH, dopamine, somatostatin, and TRH (22, 26) .
In man, on the other hand, past studies had focused on the effects of galanin on pituitary hormone secretion in vitro and in vivo (1, 13, 14, 16, 27) , whereas reports on the release of galanin itself are few and have been carried out only in vivo (28 -30) . In the human pituitary, production of galanin is confined to corticotropes, both normal and tumoral, as has been demonstrated by in situ hybridization and immunocytochemistry (18, 19) . Our study tallies nicely with this evidence and, to the best of our knowledge, is the first report of galanin release by the human pituitary, specifically by tumoral corticotropes. Indeed, the results of our in vitro experiments demonstrate that galanin release by tumoral corticotropes is stimulated in a dose-dependent manner by CRH and mirrors that of ACTH, thus pointing to the corticotropes as an important source of galanin in patients with CD.
This finding is somewhat less manifest in vivo. In fact, in patients with CD, plasma galanin levels in the dominant IPS were only slightly higher, compared with those registered at the periphery. Likewise, administration of CRH induced a modest even if significant rise in galanin levels in the IPS and at the periphery. An explanation for the paucity of in vivo results could lie in the mixed origin of galanin present in petrosal and peripheral blood. Indeed, on one side, there is the contribution of extrapituitary sources [e.g. pancreas, adrenal gland, gastrointestinal and genital tract, spinal cord, and autonomic ganglia (31) ] to peripheral levels. On the other hand, it is well known that galanin is produced by the hypothalamus and reaches the pituitary via portal blood vessels. Thus, the petrosal venous drainage system receives galanin derived from the median eminence and secreted by the anterior pituitary. This could also explain the absence of correlation between ACTH and galanin levels in the IPS despite the strong association observed in pituitary adenoma cultures. The dilution of the quota of pituitary-derived galanin might also explain the contrast between the small increase in galanin concentrations after CRH administration in vivo and the marked release we observed in vitro. Moreover, the amount of galanin released by the pituitary, during the 15 min of IPS sampling, may represent intracellular stores, whereas galanin, measured in culture medium after 4 and 24 h, likely included newly synthesized molecules also.
As regards the normal study group, our results agree with those recently published by Ceresini et al. (28) , indicating that galanin does not seem to be influenced by CRH administration in normal subjects. In this context, the same investigators failed to detect changes in peripheral galanin levels after stimuli engendering the release of catecholamines (29, 30) , notably costored with galanin in chromaffin cells (32) . Here again, however, the mixing of galanin derived from different sources must not be underestimated; and we cannot exclude that a central galanin response might have occurred also in normal subjects. Further, notwithstanding the clear evidence of galanin release by the corticotrope tumor, peripheral galanin levels were comparable in normal subjects and in patients with CD. The likely inference is that peripheral plasma galanin values do not represent a suitable tool for the study of galanin release by the pituitary.
The significance of galanin released by tumoral corticotropes awaits elucidation. Galanin may act on nearby pituicytes, as previously shown in different experimental settings (10, 12) . Galanin is a potent lactotrope growth factor (8) and might, as such, contribute to the hyperplasia of PRLreleasing cells frequently observed around corticotrope tumors (33) . In fact, PRL levels are often elevated in patients with CD (34) but exhibit a dampened response to classic lactotrope stimuli, such as TRH and metoclopramide (14, 34) . We had previously reported that PRL levels increase markedly upon infusion of galanin in patients with CD, unlike the moderate rise observed in normal subjects (14) . One possible explanation for this finding had been that of a homologous up-regulation of galanin receptors situated on lactotropes, by galanin derived from tumoral corticotropes, thus potentiating the PRL response to exogenous galanin. At the time, only histochemical evidence of galanin production by tumoral corticotropes was available; but in view of the results obtained by the present study, this hypothesis seems a likely upshot. In an alternative scenario, galanin produced by tumoral corticotropes might play a role in adenoma formation. Indeed, galanin secretion and gene expression are dramatically increased in estrogen-induced prolactinomas (7, 19, 35) and in GHRH-induced somatotrope adenomas (9) , whereas other studies demonstrated that galanin stimulates the proliferation of human small cell lung carcinomas (36) . The growth-promoting role of galanin in ACTH-secreting adenomas is, of course, speculative but may well be worth investigating.
In conclusion, our study demonstrates that galanin is released by human tumoral corticotropes and responds like a true pituitary hormone to one of the main stimuli of ACTH secretion. The role of locally produced galanin is unknown but may possibly be that of an autocrine/paracrine modulator.
